Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what we know about its safety, who is eligible for the medication and more.
Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what we know about its safety, who is eligible for the medication and more.
<iframe src="https://statesidedaily.com/embed/cluster/3867a650ea1a364b10eace28686e8d996305a819" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Access expanding for experimental weight loss drug"></iframe>
